Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration

被引:56
作者
Antonelli, Alessandro [1 ]
Ferrari, Silvia Martina [1 ]
Fallahi, Poupak [1 ]
Berti, Piero [2 ]
Materazzi, Gabriele [2 ]
Marchetti, Ivo [3 ]
Ugolini, Clara [2 ]
Basolo, Fulvio [2 ]
Miccoli, Paolo [2 ]
Ferrannini, Ele [1 ]
机构
[1] Univ Pisa, Sch Med, Dept Internal Med, I-56100 Pisa, Italy
[2] Univ Pisa, Dept Surg, I-56100 Pisa, Italy
[3] Univ Hosp Pisa, Sect Cytopathol, Div Surg Mol & Ultrastruct Pathol, Pisa, Italy
关键词
D O I
10.1530/EJE-08-0190
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Anaplastic thyroid cancer (ATC) is often unoperable and chemotherapy and radiotherapy are the main treatments. Until now primary ATC cell cultures' (ANA) have been developed from Surgical biopsies. The possibility to obtain ANA from fine-needle aspiration (FNA-ANA) and to test their sensitivity to different drugs could increase the effectiveness of treatments and avoid unnecessary surgical procedures. Design: To obtain FNA-ANA from six ATC patients before undergoing surgery and to evaluate the chemosensitivity of FNA-ANA to chemotherapeutic agents and thiazolidinediones (TZD). Methods and results: FNA-ANA from the six ATC patients were cultured in RPMI 1640 and propagated in DMEM. Chemosensitivity was evaluated by inhibiting the proliferation with increasing concentrations of five different chemotherapeutic agents (bleomycin, cisplatin. gemcitabine, etoposide. and carboplatin) or TZD (rosiglitazone). Chemotherapeutic agents significantly inhibited (P<0.0001) FNA-ANA proliferation, such as TZD (P<0.001); etoposide was the most effective in reducing cell growth. Another ANA culture for each patient was obtained from a biopsy specimen: the results for the chemosensitivity tests were similar to those obtained with FNA-ANA. The (V600E)BRAF mutation was observed in two ATC patients; the inhibition of proliferation by drugs was similar in tumors with or without (V600E)BRAF mutation. Conclusions: Our study demonstrates 1) the possibility to obtain FNA-ANA, and opens the way to the use of FNA-ANA to test the chemosensitivity to different drugs (chemotherapeutic agents or TZD: and possibly the radiosensitivity) in each patient. avoiding unnecessary surgical procedures and the administration of in active chemotherapeutics; and 2) that etoposide is highly effective in reducing ATC cell growth in vitro.
引用
收藏
页码:283 / 291
页数:9
相关论文
共 50 条
  • [1] A PHASE-I CLINICAL, PLASMA, AND CELLULAR PHARMACOLOGY STUDY OF GEMCITABINE
    ABBRUZZESE, JL
    GRUNEWALD, R
    WEEKS, EA
    GRAVEL, D
    ADAMS, T
    NOWAK, B
    MINEISHI, S
    TARASSOFF, P
    SATTERLEE, W
    RABER, MN
    PLUNKETT, W
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (03) : 491 - 498
  • [2] Peroxisomal proliferator-activated receptor-γ agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells
    Aiello, Aurora
    Pandini, Giuseppe
    Frasca, Francesco
    Conte, Enrico
    Murabito, Antonella
    Sacco, Antonella
    Genua, Marco
    Vigneri, Riccardo
    Belfiore, Antonino
    [J]. ENDOCRINOLOGY, 2006, 147 (09) : 4463 - 4475
  • [3] Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion
    Ain, KB
    Egorin, MJ
    DeSimone, PA
    [J]. THYROID, 2000, 10 (07) : 587 - 594
  • [4] Interferon-γ-inducible α-chemokine CXCL10 involvement in Graves' ophthalmopathy:: Modulation by peroxisome proliferator-activated receptor-γ agonists
    Antonelli, A
    Rotondi, M
    Ferrari, SM
    Fallahi, P
    Romagnani, P
    Franceschini, SS
    Serio, M
    Ferrannini, E
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (02) : 614 - 620
  • [5] Defective interleukin six expression and responsiveness in human mammary cells transformed by an adeno 5/SV40 hybrid virus
    Basolo, F
    Fiore, L
    Calvo, S
    Falcone, V
    Conaldi, PG
    Fontanini, G
    Caligo, AM
    Merlo, G
    Gluzman, Y
    Toniolo, A
    [J]. BRITISH JOURNAL OF CANCER, 1996, 73 (11) : 1356 - 1361
  • [6] BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment
    Begum, S
    Rosenbaum, E
    Henrique, R
    Cohen, Y
    Sidransky, D
    Westra, WH
    [J]. MODERN PATHOLOGY, 2004, 17 (11) : 1359 - 1363
  • [7] Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7
  • [8] Plitidepsin has a cytostatic effect in human undifferentiated (anaplastic) thyroid carcinoma
    Bravo, SB
    Garcia-Rendueles, MER
    Seoane, R
    Dosil, V
    Cameselle-Teijeiro, J
    López-Lázaro, L
    Zalvide, J
    Barreiro, F
    Pornbo, CM
    Alvarez, CV
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (21) : 7664 - 7673
  • [9] A multimodality therapeutic approach in anaplastic thyroid carcinoma: Study on 39 patients
    Busnardo, B
    Daniele, O
    Pelizzo, MR
    Mazzarotto, R
    Nacamulli, D
    DeVido, D
    Mian, C
    Girelli, ME
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2000, 23 (11) : 755 - 761
  • [10] Novel high-affinity PPARγ agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1
    Copland, JA
    Marlow, LA
    Kurakata, S
    Fujiwara, K
    Wong, AKC
    Kreinest, PA
    Williams, SF
    Haugen, BR
    Klopper, JP
    Smallridge, RC
    [J]. ONCOGENE, 2006, 25 (16) : 2304 - 2317